Online inquiry

IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ806MR)

This product GTTS-WQ806MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets LRRC15 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001135057.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 131578
UniProt ID Q8TF66
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ806MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ12904MR IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OTSA101-DTPA
GTTS-WQ143MR IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA 124I_WX-G250
GTTS-WQ5557MR IVTScrip™ mRNA-Anti-CD33, CDP-771(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CDP-771
GTTS-WQ7079MR IVTScrip™ mRNA-Anti-FAP, FAP-IL2v(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA FAP-IL2v
GTTS-WQ5814MR IVTScrip™ mRNA-Anti-CD40, CFZ-533(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CFZ-533
GTTS-WQ539MR IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 4D5-8
GTTS-WQ9298MR IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IMMU-132
GTTS-WQ3274MR IVTScrip™ mRNA-Anti-TNF, ART621(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ART621
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW